Ameliorative effect of mepenzolate bromide against pulmonary fibrosiss

Shota Kurotsu, Ken Ichiro Tanaka, Tomomi Niino, Teita Asano, Toshifumi Sugizaki, Arata Azuma, Hidekazu Suzuki, Tohru Mizushima

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis is thought to involve lung injury caused by reactive oxygen species (ROS), which in turn is followed by abnormal fibrosis. A transforming growth factor (TGF)- ß1-induced increase in myofibroblast number plays an important role in this abnormal fibrosis. We recently found that mepenzolate bromide (mepenzolate), which has been used clinically to treat gastrointestinal disorders, has ROS-reducing properties. In the present study, we examined the effect of mepenzolate on bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. The severity of pulmonary fibrosis was assessed by histopathologic evaluation and determination of hydroxyproline levels. Lung mechanics (elastance) and respiratory function [forced vital capacity (FVC)] were assessed using a computer-controlled ventilator. Respiratory function was also evaluated by monitoring percutaneous arterial oxygen saturation (SpO 2). Intratracheal administration of mepenzolate prior to bleomycin treatment reduced the extent of pulmonary fibrosis and changes in lung mechanics and led to a significant recovery of both FVC and SpO2 compared with control. Furthermore, mepenzolate produced a therapeutic effect even when it was administered after the development of fibrosis. Administration of mepenzolate also prevented bleomycin-induced pulmonary cell death and inflammatory responses and increased myofibroblast number. Mepenzolate also decreased NADPH oxidase activity and active TGF-ß1 level or increased glutathione S-transferase (GST) activity in the presence of bleomycin treatment. These results show that the intratracheal administration of mepenzolate reduced bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. These effects may be due to this drug's inhibitory effect on NADPH oxidase and TGF-ß1 activities and its stimulatory effect on GST.

Original languageEnglish
Pages (from-to)79-88
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume350
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Lung
Pulmonary Fibrosis
Bleomycin
Transforming Growth Factors
Fibrosis
Myofibroblasts
NADPH Oxidase
Vital Capacity
Glutathione Transferase
Reactive Oxygen Species
Respiratory Mechanics
Idiopathic Pulmonary Fibrosis
mepenzolic acid
Hydroxyproline
Lung Injury
Therapeutic Uses
Mechanical Ventilators
Mechanics
Cell Death
Oxygen

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Kurotsu, S., Tanaka, K. I., Niino, T., Asano, T., Sugizaki, T., Azuma, A., ... Mizushima, T. (2014). Ameliorative effect of mepenzolate bromide against pulmonary fibrosiss. Journal of Pharmacology and Experimental Therapeutics, 350(1), 79-88. https://doi.org/10.1124/jpet.114.213009

Ameliorative effect of mepenzolate bromide against pulmonary fibrosiss. / Kurotsu, Shota; Tanaka, Ken Ichiro; Niino, Tomomi; Asano, Teita; Sugizaki, Toshifumi; Azuma, Arata; Suzuki, Hidekazu; Mizushima, Tohru.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 350, No. 1, 2014, p. 79-88.

Research output: Contribution to journalArticle

Kurotsu, S, Tanaka, KI, Niino, T, Asano, T, Sugizaki, T, Azuma, A, Suzuki, H & Mizushima, T 2014, 'Ameliorative effect of mepenzolate bromide against pulmonary fibrosiss', Journal of Pharmacology and Experimental Therapeutics, vol. 350, no. 1, pp. 79-88. https://doi.org/10.1124/jpet.114.213009
Kurotsu, Shota ; Tanaka, Ken Ichiro ; Niino, Tomomi ; Asano, Teita ; Sugizaki, Toshifumi ; Azuma, Arata ; Suzuki, Hidekazu ; Mizushima, Tohru. / Ameliorative effect of mepenzolate bromide against pulmonary fibrosiss. In: Journal of Pharmacology and Experimental Therapeutics. 2014 ; Vol. 350, No. 1. pp. 79-88.
@article{fc67a012f196446aa8f861f76db0d01f,
title = "Ameliorative effect of mepenzolate bromide against pulmonary fibrosiss",
abstract = "Idiopathic pulmonary fibrosis is thought to involve lung injury caused by reactive oxygen species (ROS), which in turn is followed by abnormal fibrosis. A transforming growth factor (TGF)- {\ss}1-induced increase in myofibroblast number plays an important role in this abnormal fibrosis. We recently found that mepenzolate bromide (mepenzolate), which has been used clinically to treat gastrointestinal disorders, has ROS-reducing properties. In the present study, we examined the effect of mepenzolate on bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. The severity of pulmonary fibrosis was assessed by histopathologic evaluation and determination of hydroxyproline levels. Lung mechanics (elastance) and respiratory function [forced vital capacity (FVC)] were assessed using a computer-controlled ventilator. Respiratory function was also evaluated by monitoring percutaneous arterial oxygen saturation (SpO 2). Intratracheal administration of mepenzolate prior to bleomycin treatment reduced the extent of pulmonary fibrosis and changes in lung mechanics and led to a significant recovery of both FVC and SpO2 compared with control. Furthermore, mepenzolate produced a therapeutic effect even when it was administered after the development of fibrosis. Administration of mepenzolate also prevented bleomycin-induced pulmonary cell death and inflammatory responses and increased myofibroblast number. Mepenzolate also decreased NADPH oxidase activity and active TGF-{\ss}1 level or increased glutathione S-transferase (GST) activity in the presence of bleomycin treatment. These results show that the intratracheal administration of mepenzolate reduced bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. These effects may be due to this drug's inhibitory effect on NADPH oxidase and TGF-{\ss}1 activities and its stimulatory effect on GST.",
author = "Shota Kurotsu and Tanaka, {Ken Ichiro} and Tomomi Niino and Teita Asano and Toshifumi Sugizaki and Arata Azuma and Hidekazu Suzuki and Tohru Mizushima",
year = "2014",
doi = "10.1124/jpet.114.213009",
language = "English",
volume = "350",
pages = "79--88",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Ameliorative effect of mepenzolate bromide against pulmonary fibrosiss

AU - Kurotsu, Shota

AU - Tanaka, Ken Ichiro

AU - Niino, Tomomi

AU - Asano, Teita

AU - Sugizaki, Toshifumi

AU - Azuma, Arata

AU - Suzuki, Hidekazu

AU - Mizushima, Tohru

PY - 2014

Y1 - 2014

N2 - Idiopathic pulmonary fibrosis is thought to involve lung injury caused by reactive oxygen species (ROS), which in turn is followed by abnormal fibrosis. A transforming growth factor (TGF)- ß1-induced increase in myofibroblast number plays an important role in this abnormal fibrosis. We recently found that mepenzolate bromide (mepenzolate), which has been used clinically to treat gastrointestinal disorders, has ROS-reducing properties. In the present study, we examined the effect of mepenzolate on bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. The severity of pulmonary fibrosis was assessed by histopathologic evaluation and determination of hydroxyproline levels. Lung mechanics (elastance) and respiratory function [forced vital capacity (FVC)] were assessed using a computer-controlled ventilator. Respiratory function was also evaluated by monitoring percutaneous arterial oxygen saturation (SpO 2). Intratracheal administration of mepenzolate prior to bleomycin treatment reduced the extent of pulmonary fibrosis and changes in lung mechanics and led to a significant recovery of both FVC and SpO2 compared with control. Furthermore, mepenzolate produced a therapeutic effect even when it was administered after the development of fibrosis. Administration of mepenzolate also prevented bleomycin-induced pulmonary cell death and inflammatory responses and increased myofibroblast number. Mepenzolate also decreased NADPH oxidase activity and active TGF-ß1 level or increased glutathione S-transferase (GST) activity in the presence of bleomycin treatment. These results show that the intratracheal administration of mepenzolate reduced bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. These effects may be due to this drug's inhibitory effect on NADPH oxidase and TGF-ß1 activities and its stimulatory effect on GST.

AB - Idiopathic pulmonary fibrosis is thought to involve lung injury caused by reactive oxygen species (ROS), which in turn is followed by abnormal fibrosis. A transforming growth factor (TGF)- ß1-induced increase in myofibroblast number plays an important role in this abnormal fibrosis. We recently found that mepenzolate bromide (mepenzolate), which has been used clinically to treat gastrointestinal disorders, has ROS-reducing properties. In the present study, we examined the effect of mepenzolate on bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. The severity of pulmonary fibrosis was assessed by histopathologic evaluation and determination of hydroxyproline levels. Lung mechanics (elastance) and respiratory function [forced vital capacity (FVC)] were assessed using a computer-controlled ventilator. Respiratory function was also evaluated by monitoring percutaneous arterial oxygen saturation (SpO 2). Intratracheal administration of mepenzolate prior to bleomycin treatment reduced the extent of pulmonary fibrosis and changes in lung mechanics and led to a significant recovery of both FVC and SpO2 compared with control. Furthermore, mepenzolate produced a therapeutic effect even when it was administered after the development of fibrosis. Administration of mepenzolate also prevented bleomycin-induced pulmonary cell death and inflammatory responses and increased myofibroblast number. Mepenzolate also decreased NADPH oxidase activity and active TGF-ß1 level or increased glutathione S-transferase (GST) activity in the presence of bleomycin treatment. These results show that the intratracheal administration of mepenzolate reduced bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. These effects may be due to this drug's inhibitory effect on NADPH oxidase and TGF-ß1 activities and its stimulatory effect on GST.

UR - http://www.scopus.com/inward/record.url?scp=84903546729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903546729&partnerID=8YFLogxK

U2 - 10.1124/jpet.114.213009

DO - 10.1124/jpet.114.213009

M3 - Article

C2 - 24769542

AN - SCOPUS:84903546729

VL - 350

SP - 79

EP - 88

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -